Minnesota spin-out Embomedics secures $860k series A for disappearing drug delivery system.

Embomedics, a life sciences spin-out of the University of Minnesota, has raised $860k in a series A round, according to a filing with the SEC. The round, which was supported by a range of angel investors, will go towards the development of Embomedic’s primary technology. The firm is commercialising medtech developed at Minnesota which acts…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.